Uniunea Europeană - română - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - mielom multiplu - agenți antineoplazici - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

janssen biologics b.v. - olanda - teclistamabum - sol inj. - 10mg/ml

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

janssen biologics b.v. - olanda - teclistamabum - sol inj. - 90mg/ml

Uniunea Europeană - română - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - mielom multiplu - agenți antineoplazici - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.